FDG PET imaging in patients with pathologically verified dementia

Journal of Nuclear Medicine

Volumn 41, Issue 11, 2000, Pages 1920-1928

  Hoffman, J M ^a   Welsh Bohmer, K A ^a   Hanson, M ^a   Crain, B ^a   Hulette, C ^a   Earl, N ^a   Coleman, R E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Dementia; FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MALE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PARIETAL LOBE; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033767352     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. The use of positron emission tomography in the clinical assessment of dementia
2. [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia
3. Brain blood flow in the dementias: SPECT with histopathologic correlation
4. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: A critical review
5. Quantitative brain SPECT in Alzheimer's disease and normal aging
6. The scintigraphic appearance of Alzheimer's disease: A prospective study using technetium-99m-HMPAO SPECT
7. Functional brain imaging in Alzheimer's-type dementia
8. Differential diagnosis of Alzheimer's disease with PET
9. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography
10. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of flourine-18-FDG PET
11. Early detection of Alzheimer's disease: A statistical approach using positron emission tomographic data
12. Comparability of FDG PET studies in probable Alzheimer's disease
13. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease
14. Temporal parietal hypoperfusion with single-photon emission computerized tomography in conditions other than Alzheimer's disease
15. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease
16. Pathological and positron emission tomographic correlations in Alzheimer's disease
17. Comparison of PET, MRI and CT with pathology in a proven case of Alzheimer's disease
18. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease
19. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer's cases, including 13 serial scans
20. Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease
21. Lack of correlation of regional neuropathology to the regional PET metabolic deficits in Alzheimer's disease
22. Post-mortem neurofibrillary tangle densities but not senile plaque densities are related to regional metabolic rates for glucose during life in Alzheimer's disease patients
23. Normal pressure hydrocephalus
24. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease
25. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease
26. Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part 1. Clinical and neuropsychological assessment of AD
27. 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in dementia
28. Detection and staging of dementia in Alzheimer's disease: Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
29. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V: A normative study of the neuropsychological battery
30. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
31. Bitemporal hypometabolism in Creutzfeldt-Jacob disease measured by positron emission tomography with [18F]-2-fluorodeozyglucose
32. Brain glucose metabolism in a patient with Creutzfeldt-Jacob disease measured by positron emission tomography
33. Beware the classic FDG-PET pattern of Alzheimer's disease
34. PET studies in progressive supranuclear palsy
35. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy
36. Positron emission tomography study in progressive supranuclear palsy: Brain hypometabolic pattern and clinicometabolic correlations
37. Single photon emission computed tomographic perfusion imaging in autopsy-diagnosed dementia
38. SPECT in dementia: Clinical and pathological correlation
39. The diagnosis of Alzheimer's disease: A question of image?
40. Autopsy: Consent, completion and communication in Alzheimer's disease research
41. Comparison of pathological diagnostic criteria for Alzheimer disease
42. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinicopathologic study of 57 cases
43. Diagnosis of Alzheimer's disease
44. The differential diagnosis of Alzheimer's disease: Conceptual and methodological issues
45. Neuropathological staging of Alzheimer-related changes
46. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease
47. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
48. Application of the National Institute on Aging (NIA)-Reagan Institute Criteria for the neuropathological diagnosis of Alzheimer disease
49. Alzheimer's disease; glutamate depletion in the hippocampal perforant pathway zone
50. Neural correlates of cognitive impairment in Alzheimer's disease
51. A new definition of Alzheimer's disease: A hippocampal dementia
52. Pathological alterations in the amygdala in Alzheimer's disease
53. Neuranatomical and neuropathological changes in normal aging and in dementia
54. Distribution of neurofibrillary tangles and neuritic placques in the cerebral cortex in Alzheimer's disease
55. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease
56. Glucose metabolism as the sight of the primary abnormality in early-onset dementia of Alzheimer type?
57. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynmnic FDG-PET
58. Diminished glucose transport in Alzheimer's disease: Dynamic PET studies
59. Correction of positron emission tomography data for cerebral atrophy
60. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging